Is Alnylam Pharmaceuticals Inc (ALNY) overvalued? · P/E 76, rev $1.29B
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
This page asks whether Alnylam Pharmaceuticals Inc (ALNY) looks expensive on cached numbers — not a short thesis.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ALNY 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ALNY stock page for the full model, not this heading.
Not investment advice.